BioGenerator is an evergreen investor that creates, grows, and invests in promising companies and entrepreneurs in the St. Louis region. BioGenerator identifies and de-risks commercially promising innovations and services; advises innovators and entrepreneurs; recruits and supports entrepreneurial talent; makes staged investments grounded in rigorous due diligence; and offers access to lab space and capital equipment. We position companies to navigate the unique challenges of early-stage bioscience company development.
BioGenerator is the investment arm of BioSTL
Adarza is a next-generation multiplex immunoassay product company focused on applications in life science tools and the in vitro diagnostics markets. Adarza’s products and services utilize its proprietary Arrayed Imaging Reflectometry™ (“AIR”) detection platform that is capable of rapid identification and quantification and offers key performance benefits in multiplexing, sensitivity, speed, sample size, dynamic range, and ease of use while affording industry-leading low cost. The AIR platform addresses many commercial applications, including disease biomarkers, personalized medicine, drug and vaccine development, allergy, immunology, and infectious diseases research.
The BioGenerator portfolio is a compilation of companies within the health and plant sciences including therapeutics, diagnostics, medical devices, research tools, agriculture and IT.
The BioGenerator portfolio includes companies within the health and plant sciences including therapeutics, diagnostics, medical devices, research tools, agriculture and IT.
"I think BioGenerator is a supremely unique asset. That combination of attributes – funding, physical assets, and network – in a single organization was a huge factor in our decision to move the company here."
– Chad Stiening
CEO and Founder, Kypha
Stay up to date with the latest BioGenerator news and details.